MilliporeSigma opens Chinese bioprocessing centre to showcase tech

By Staff Reporter

- Last updated on GMT

Image: GettyImages/dk1234
Image: GettyImages/dk1234

Related tags Pharmacology

MilliporeSigma has opened a biopharma process development and technology centre in China.

The site in Shanghai, China will offer biopharma customers access to MilliporeSigma’s range of end-to-end process development capabilities and services, including cell line development, upstream and downstream process development and non-GMP clinical production.

The centre will be operated under the Bioreliance brand, added to Germany’s Merck through its acquisition of Sigma-Aldrich in 2015​, and is the first such centre to open its doors outside of Europe.

“Our new BioReliance End-to-End Biodevelopment Center will host small-scale drug manufacturers working on early-phase clinical trials,”​ MilliporeSigma CEO Udit Batra said in a statement.

It is designed to target customers in the APAC region through an integrated suite of services for biopharmaceutical helping to accelerate clinical drug development from molecule to commercial production.

The centre is modelled on the firm’s site in Martillac, France which offers a single-use, GMP facility for manufacturing clinical-stage batches and is equipped with MilliporeSigma technologies, including the 2000-liter single-use Mobius bioreactor.

The firm has also planned a 280,000 sq ft facility in Burlington, Massachusetts.

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more